UK Notes PPI Dermatosis Risk: Will FDA Make Similar Communication?
This article was originally published in The Tan Sheet
Executive Summary
The UK drug regulator announces “a very low risk” of sub-acute cutaneous lupus erythematosus from use of PPIs, which are available there with the same ingredients approved for use in the US in products available OTC and RX – esomeprazole, lansoprazole and omeprazole – and Rx only, pantoprazole and rabeprazole.
You may also be interested in...
UK Nexium Ad Rapped For Downplaying Treatment For Persistent Heartburn
Pfizer’s TV ad for Nexium Control short-term heartburn treatment implied consumers with persistent heartburn need not seek professional medical advice, UK Advertising Standards Authority says. Pfizer argued that information in the ad was in line with MHRA's approval for the drug’s indications and packaging warned consumers not to use more than 14 days.
Zegerid OTC, Private Label Omeprazole Add Drug Interaction Warnings
CDER approves sNDAs from Bayer for Zegerid OTC powder and private label manufacturer Dexcel Pharma for omeprazole delayed release tablets to add label warnings on drug-drug interactions for methotrexate and mycophenolate mofetil.
Public Citizen Urges FDA To Add Sweeping Warnings To PPI Labels
Public Citizen petitions FDA to add several warnings to all proton pump inhibitors, including OTCs – which the agency previously determined do not pose the same level of risk as prescription versions.